Tesaro, Inc., Breast International Group (BIG), and the European Organization for Research and Treatment of Cancer Announce Collaboration for Niraparib Clinical Development in Breast Cancer
6/3/2013 9:38:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHICAGO and BRUSSELS, Belgium, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, Breast International Group (BIG), a non-profit organization for academic breast cancer research groups from around the world, and the European Organization for Research and Treatment of Cancer (EORTC), an international, independent, multidisciplinary non-profit research organization, today announced a partnership for the Phase 3 clinical development of niraparib, an orally active, potent poly (ADP-ribose) polymerase (PARP) inhibitor.
Help employers find you! Check out all the jobs and post your resume.